|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM180076655 |
| 003 |
DE-627 |
| 005 |
20250209130444.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2008 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2008.04.007
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0600.xml
|
| 035 |
|
|
|a (DE-627)NLM180076655
|
| 035 |
|
|
|a (NLM)18539537
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wiesemann, Elke
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis
|
| 264 |
|
1 |
|c 2008
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.09.2008
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Interferon-beta (IFN-beta) is an effective treatment for a subgroup of patients with multiple sclerosis (MS). The mechanism of action as well as the pathophysiological basis of responsiveness to IFN-beta is not well understood. To improve treatment considerations in MS patients predictive markers for response to IFN-beta therapy at early timepoints are needed. Here we correlated changes in serum cytokine levels (IL-13, IL-10, IL-5, IL-4, IFN-gamma) with the clinical response to IFN-beta treatment. Serum cytokine levels of 77 untreated and 43 IFN-beta treated relapsing-remitting MS patients (RRMS) were measured by ELISA, including longitudinal measurements in 17 patients. We found a significant upregulation of IL-10 and IL-5 serum cytokine levels during IFN-beta therapy. However, clinical response was only associated with IL-10 serum levels (p=0.038; positive predictive value 0.95, negative predictive value 0.43) but not with IL-5. The predictive power was increased by a combined testing of IL-10 with expression of co-signaling molecules on monocytes, that were previously shown to change during IFN-beta therapy. In a subgroup of 17 patients testing of 4 markers had a positive and negative predictive value of 1.0 for at least 2 of these markers being positive in treatment responders. The results suggest that serum IL-10 is useful to predict treatment response to IFN-beta particularly in combination with a panel of other IFN-beta dependent parameters
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a B7-2 Antigen
|2 NLM
|
| 650 |
|
7 |
|a CD40 Antigens
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Intercellular Signaling Peptides and Proteins
|2 NLM
|
| 650 |
|
7 |
|a PDCD1LG2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Programmed Cell Death 1 Ligand 2 Protein
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 650 |
|
7 |
|a Interferon-beta
|2 NLM
|
| 650 |
|
7 |
|a 77238-31-4
|2 NLM
|
| 700 |
1 |
|
|a Deb, Milani
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hemmer, Bernhard
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Radeke, Heinfried H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Windhagen, Anja
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 128(2008), 3 vom: 01. Sept., Seite 306-13
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:128
|g year:2008
|g number:3
|g day:01
|g month:09
|g pages:306-13
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2008.04.007
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 128
|j 2008
|e 3
|b 01
|c 09
|h 306-13
|